BioLineRx Ltd. (BLRX) stock
BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.15+0.03 (+2.68%)
Close on Nov 18, 2026Market cap $5.00MP/E –Yield –
Earnings
BioLineRx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q2 FY2026
$300.00K
EPS, Q2 FY2026
$0.00
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of BioLineRx's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | Aug 31, 2026before the open | $300.00K | – | $0.00 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 23, 2026before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 31, 2025before the open | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 15, 2024before the open | $5.40M | – | $0.00 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 26, 2024before the open | $4.80M | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 22, 2023before the open | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 16, 2022before the open | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
BioLineRx has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When BioLineRx puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases BioLineRx filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?